Motufe (Fluticasone Furoate)

Fluticasone furoate binds to glucocorticoid receptors in the cells lining the nasal passages. This binding alters gene expression, suppressing inflammatory cytokines and reducing swelling, mucus production, and immune cell infiltration, which together relieve nasal inflammation and related symptoms.

The appropriate dose of Motufe is determined by a qualified prescriber based on the patient’s condition, age, and response to therapy. Healthcare professionals tailor the regimen to achieve optimal symptom control while minimizing potential side effects.

Safety data for Motufe in pregnancy and lactation are limited. Women who are pregnant, planning to become pregnant, or breastfeeding should discuss potential risks and benefits with their healthcare provider before starting treatment.

To order Motufe, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements), and necessary import documentation.

Motufe’s active ingredient, fluticasone furoate, has a high receptor affinity and a long residence time in nasal tissues, allowing once‑daily dosing for many patients. Compared with older agents such as fluticasone propionate or budesonide, it may provide comparable efficacy with a convenient dosing schedule, though individual response can vary.

Motufe should be stored at room temperature, away from excessive heat and moisture. Keep the spray in its original packaging until use, and protect the nozzle from contamination. Do not freeze the product, and discard any spray that appears discolored or has an unusual odor.

Motufe is administered as a nasal spray. The recommended technique is to gently blow the nose, tilt the head slightly forward, insert the nozzle into one nostril, and spray the prescribed number of sprays while breathing in gently. Repeat in the other nostril if directed by the prescriber.

Serious risks, although rare, include nasal septal perforation, severe allergic reactions such as anaphylaxis, vision changes (e.g., cataracts or glaucoma), and systemic adrenal suppression with prolonged high‑dose use. Patients should seek immediate medical attention if they experience unusual bleeding, persistent eye problems, or signs of an allergic reaction.

Motufe should be avoided in individuals with known hypersensitivity to fluticasone furoate or any component of the formulation. It is also contraindicated in patients with active untreated nasal infections, recent nasal surgery without physician approval, or those who have experienced severe adverse reactions to other nasal corticosteroids.